Venture Capital
EMERYVILLE, Calif.--(BUSINESS WIRE)--Zymergen, the world’s first molecular manufacturing technology company, announced today it has raised over $400 million in Series C funding led by returning investor SoftBank Vision Fund. The round welcomes new investors Goldman Sachs and Hanwha Asset Management, as well as returning investors, DCVC (Data Collective), True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors. Industrial progress has not kept pace with the demands of today. Petroleum co.

In this article